Sight Sciences reports Q4 2025 revenue up 7% YoY; FY 2025 revenue down 3% YoY

Sight Sciences, Inc.

2025-FY EPS reported -$0.74 revenue$77,363,000

Q4 2025 total revenue $20.3M-$20.4M, +7% vs Q4 2024; Surgical Glaucoma +5%, Dry Eye +130%.
Full year 2025 revenue $77.3M-$77.4M, down 3% vs 2024; Surgical Glaucoma flat, Dry Eye ~$1.6M (from $4.0M).
Cash and equivalents ~$92M; Q4 cash burn ~$0.4M, FY cash used ~$28M.
Management reiterates path to cash flow breakeven without additional equity; complete results expected March 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.